Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+  locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

ConclusionBuparlisib plus trastuzumab, as a chemotherapy-free regimen, demonstrated an acceptable safety profile but limited efficacy in patients with heavily pretreated, trastuzumab-resistant HER2-positive breast cancer, and in patients with progressive brain metastases also receiving capecitabine.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research